The Basal Cell Carcinoma (Basal Cell Epithelioma) drugs in development market research report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Basal Cell Carcinoma (Basal Cell Epithelioma). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued products.
GlobalData tracks 63 drugs in development for Basal Cell Carcinoma (Basal Cell Epithelioma) by 55 companies/universities/institutes. The top development phase for Basal Cell Carcinoma (Basal Cell Epithelioma) is phase ii with 31 drugs in that stage. The Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline has 62 drugs in development by companies and one by universities/ institutes. Some of the companies in the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline products market are: Bristol-Myers Squibb, Palvella Therapeutics and MediWound.
The key targets in the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline products market include Programmed Cell Death Protein 1, Smoothened Homolog, and Cytotoxic T Lymphocyte Protein 4.
The key mechanisms of action in the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline product include Programmed Cell Death Protein 1 Antagonist with five drugs in Phase II. The Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline products include 16 routes of administration with the top ROA being Topical and 17 key molecule types in the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline products market including Small Molecule, and Monoclonal Antibody.
Basal Cell Carcinoma (Basal Cell Epithelioma) overview
Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include a waxy bump; a scaly, brown, or flesh-colored patch; or a white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.
For a complete picture of Basal Cell Carcinoma (Basal Cell Epithelioma)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
